Evidence map›Paper›PMID 35935048›Full record

ReviewAdvanced pharmaceutical bulletin2022

Multiwalled Carbon Nanotubes as Nanomaterial Tool in the Management of Prostate Cancer: A Possible Nanoformulation Approach.

Raja Murugesan, Raman Sureshkumar, Arun Radhakrishnan, Srikanth Jupudi, Manisha Chennu

Open access · diamondAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Advanced pharmaceutical bulletin, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.1field-weighted citation impact, top 55% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Raja MurugesanDepartment of Pharmaceutics, JSS College of Pharmacy, JSS Academy of Higher Education & Research, Ooty, India.ORCID https://orcid.org/0000-0002-9786-5697
Raman SureshkumarDepartment of Pharmaceutics, JSS College of Pharmacy, JSS Academy of Higher Education & Research, Ooty, India.ORCID https://orcid.org/0000-0002-9764-0121
Arun RadhakrishnanDepartment of Pharmaceutics, JSS College of Pharmacy, JSS Academy of Higher Education & Research, Ooty, India.
Srikanth JupudiDepartment of Pharmaceutical Chemistry, JSS College of Pharmacy, JSS Academy of Higher Education & Research, Ooty, India.
Manisha ChennuDepartment of Pharmacology, JSS College of Pharmacy, JSS Academy of Higher Education & Research, Ooty, India.
JSS Academy of Higher Education and Research · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Prostate cancer (PCa) is one of the leading diseases in men all over the world caused due to over-expression of prostate-specific membrane antigen (PSMA). Currently, the detection and targeting of PCa is one of the major challenges in the prostate gland. Therefore, Bruton tyrosine kinase inhibitor molecules like ibrutinib (Ibr) loaded with nanomaterials like multi-walled carbon nanotubes (MWCNTs), which has good physico-chemical properties may be the best regimen to treat PCa. In this strategy, the chemically modified MWCNTs have excellent 'Biosensing' properties makes it easy for detecting PCa without fluorescent agent and thus targets particular site of PCa. In the present study, Ibr/MWCNTs conjugated with T

Indexed as

Carbon nanotubesDrug deliveryIn silico studiesProstate cancer

Identifiers

PMID35935048
PMCPMC9348525
OpenAlexW3210795127

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.